Systematic review and meta-analysis of 22 observational studies (3361 patients) with drug-resistant Pseudomonas aeruginosa: ceftolozane-tazobactam vs ceftazidime-avibactam showed no significant differences in mortality, clinical response, AKI or resistance emergence.
Meta-analysisn = 3,361
Li et al. Comparison of ceftolozane-tazobactam and ceftazidime-avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: an updated systematic review and meta-analysis based on adjusted data from observational studies